EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
PR Newswire —
Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life Sciences from the LSP Dementia Fund, together with age1 and participation from laso Ventures,...